Cargando…
498. Covid-19 Hospitalization Rates in Kidney Transplant Patients Treated with Tixagevimab/Cilgavimab
BACKGROUND: Tixagevimab/cilgavimab (T/C) is a monoclonal antibody that was previously authorized for pre-exposure prophylaxis of COVID-19 in individuals with moderate to severe immune compromise. Limited evidence of safety and efficacy in immunocompromised populations was available at the time of au...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677660/ http://dx.doi.org/10.1093/ofid/ofad500.567 |